AMDL Signs Third Significant Distribution Relationship to Help Complete Distribution in Chinese Market
May 30 2007 - 10:00AM
PR Newswire (US)
TUSTIN, Calif., May 30 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (Jade), is an international
biopharma company and AMDL, together with Jade, engages in the
development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products. AMDL announced today that
Jade, through its subsidiary JJB, has signed a new Distribution and
Agency Agreement with Anhui Huayuan Medical Co. Ltd., (AHM) a
direct subsidiary of China Resources (Holdings) Co., Ltd. (China
Resources). This one-year renewable agreement covers primarily the
provinces and cities of Anhui, Shandong, Hebei, Shanxi, Beijing,
Tianjing. AHM will initially be selling 12 Jade products including
Ondansetron injectables, Domperidon tablets, Chondroitin Sulfate
injectables, GuYanLin compounds, Benzoic Acid /Camphor solutions,
Levofloxacin and Lactate injectables and others. Mr. Frank Zheng,
Managing Director of Jade, stated that "this new distribution
agreement with AHM coupled with the two new distribution
relationships recently announced with Double Crane Medicine Co.
Ltd. (Changsha), and Shanghai SiFul Medicine Co., Ltd., all require
JJB's distribution partners to meet minimum sales thresholds of
approximately (US) $3.8 million annually for each distribution
agreement or a total of approximately (US) $11.4 million for all of
these distribution contracts. Based upon all three distribution
agreements and discussions between JJB and its new distribution
partners, we believe that there is a potential to increase JPI's
sales in Northern China and also the Shanghai regional markets by
as much as (US) $24 million over the next 12 month sales cycle.
Domperidone tablets are expected to be the largest selling product
in these Northern China marketplaces," Mr. Zheng said. Mr. Gary
Dreher, CEO of AMDL noted that "this new regional Chinese
distribution relationship with AHM is truly exciting and
significantly enhances Jade's ability to grow its sales in these
Northern China markets." About Jade: Jade has access to the fastest
growing pharmaceutical and consumer market in the world: China.
AMDL, through its subsidiaries, Jade currently manufactures large
volume injection fluids, tablets and other related products,
holding licenses for 133 products. It also manufactures 107
generic, over the counter and supplemental pharmaceutical products
under certified Chinese Good Manufacturing Practice (CGMP)
standards. About Anhui Medical: AHM was found in 1953, and is one
of the largest pharmaceutical distributors in China with products
ranging from new medicines, generic medicine and health
supplements. AHM was recently acquired by China Resource (Holdings)
Co., Ltd., which formed one of the largest pharmaceutical
businesses in China. China Resource (Holdings), with (U.S.) $8
billion in revenues has four listed subsidiaries on the Hong Kong
Stock Exchange, including China Resources Enterprise, Ltd. (Hong
Kong Stock Code: 0291), ADR: CRHKY and on the London Stock Exchange
and other international exchanges. Currently, AHM has a sales and
marketing network that includes more than 4,400 local and
provincial based pharmaceutical distributors selling over 25,000
medical products nationwide in China. AHM is ranked as one of the
top 3 pharmaceutical distributors in China. In 2006, AHM had sales
of approximately US$1.2 billion. In 2003, AHM built the first
online pharmacy in China and is currently the largest on-line
pharmacy in China. About AMDL: More information about AMDL and its
products can be obtained at http://www.amdl.com/. Forward-Looking
Statements: This news release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements are subject to certain risks and
uncertainties, and actual circumstances, events or results may
differ materially from those projected in such forward-looking
statements. The Company cautions readers not to place undue
reliance on any forward-looking statements. The Company does not
undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or
unanticipated events as they occur. Contact: AMDL, Inc. Gary L.
Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc.
CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc.,
+1-714-505-4460 Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024